Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Tuesday Ahead of Consumer Confidence Data, US Treasury Buyback Announcement
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Catalyst Pharma's FIRDAPSE Approved in Japan for Rare Autoimmune Disorder Lambert-Eaton Myasthenic Syndrome ("LEMS")
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan
High Growth Tech Stocks In The United States You Should Know
Despite the Downward Trend in Earnings at Catalyst Pharmaceuticals (NASDAQ:CPRX) the Stock Grows 4.2%, Bringing Three-year Gains to 288%
Catalyst Pharmaceuticals(CPRX.US) Officer Sells US$3.05 Million in Common Stock
Insider Sale at Catalyst Pharmaceuticals Inc (CPRX): Chief Operating & Scientific Officer ...
Form 144 | Catalyst Pharmaceuticals(CPRX.US) Officer Proposes to Sell 3.06 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Aug 20, $Catalyst Pharmaceuticals(CPRX.US)$ Officer Miller Steve intends to sell 150K shares of its common stock on Aug 20, with a total market value of approximately $3.06
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
Wall Street Analysts See a 56.65% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
The Latest Analyst Ratings For Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Express News | Catalyst Pharmaceuticals : H.c. Wainwright Raises Target Price to $30 From $26
Piper Lists Eight Defensive Biotechs to Face Market Volatility
Express News | Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $31
Express News | Catalyst Pharmaceuticals Shares Fall to Session Low of $17.58 in Volume Jump, Last Down 0.9% at $18.13
Catalyst Pharmaceuticals Analyst Ratings
Earnings Call: Catalyst Pharmaceuticals Sees Robust Q2 Growth
Express News | Catalyst Pharmaceuticals Inc : Citigroup Raises Target Price to $31 From $27